Cyfuse Biomedical K.K.
Cyfuse Biomedical K.K. scores highest on Nitro (45) and lowest on Earnings (8). Its PosiPenta is 22.86 out of 100, weaker than most similar companies.
On the Penta Grid this week, Cyfuse Biomedical K.K. is Grid #53 of 53 in the Healthcare sector in Japan, and Grid #1,049 of 1,059 in Japan.
Compared with similar companies in the Healthcare sector in Japan.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Cyfuse Biomedical K.K. | 22.86 | 16 | 8 | 45 | 25 | 21 |
| SUSMED,Inc. | 33.21 | 28 | 50 | 3 | 57 | 29 |
| Nippon Chemiphar Co., Ltd. | 36.69 | 50 | 13 | 41 | 22 | 58 |
| CellSource Co., Ltd. | 46.66 | 42 | 60 | 20 | 77 | 35 |
| PRISM BioLab Co.,LTD | 23.97 | 13 | 16 | 17 | 53 | 21 |
| Hi-CRATES CO.,LTD. | 68.48 | 80 | 55 | 65 | 83 | 60 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -6.93 |
| P/B ratio | 2.17 |
EEarnings
| Trailing EPS | ₹-49.26 |
| Forward EPS | — |
NNitro
| Price | 341.43 |
| 52-week high | 462.50 |
| 52-week low | 294.81 |
| Fall from 52-week high | 26.2% |
TTorque
| Return on equity (ROE) | -32.12% |
| Debt-to-equity | 0.47 |
AAnchor
| Beta (price swings) | 1.27 |
| Market cap | ₹344 Cr |
| Insider holding | 29.16% |
| Dividend yield | 0.00% |
Figures as used for the week of 24 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Cyfuse Biomedical K.K.'s PosiPenta score?
Cyfuse Biomedical K.K.'s PosiPenta is 22.86 out of 100 for the week of 24 Oct 2026, based on 5 of 5 pillars.
Where does Cyfuse Biomedical K.K. stand on the Penta Grid?
On the Penta Grid this week, Cyfuse Biomedical K.K. is Grid #53 of 53 in the Healthcare sector in Japan, and Grid #1,049 of 1,059 in Japan.
Which PosiPenta pillar is strongest for Cyfuse Biomedical K.K.?
Nitro (momentum), with a score of 45 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for Cyfuse Biomedical K.K.?
Earnings (growth), with a score of 8 out of 100: much weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.